174 related articles for article (PubMed ID: 33208875)
1. Clinical usefulness of high levels of C-reactive protein for diagnosing epithelial ovarian cancer.
Yang D; Li H; Sun X; Yang S; Wang K; Liu Z
Sci Rep; 2020 Nov; 10(1):20056. PubMed ID: 33208875
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
3. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic Performance of Serum Human Epididymis Protein 4 (HE4) for Prediction of Malignancy in Ovarian Masses.
Dewan R; Dewan A; Jindal M; Bhardawaj M
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1103-1108. PubMed ID: 31030480
[TBL] [Abstract][Full Text] [Related]
5. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
6. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
7. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
[TBL] [Abstract][Full Text] [Related]
9. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
10. Role of serum HE4 as a prognostic marker in carcinoma of the ovary.
Lakshmanan M; Kumar V; Chaturvedi A; Misra S; Gupta S; Akhtar N; Rajan S; Jain K; Garg S
Indian J Cancer; 2019; 56(3):216-221. PubMed ID: 31389384
[TBL] [Abstract][Full Text] [Related]
11. Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors.
Carbotti G; Orengo AM; Mezzanzanica D; Bagnoli M; Brizzolara A; Emionite L; Puppo A; Centurioni MG; Bruzzone M; Marroni P; Rossello A; Canevari S; Ferrini S; Fabbi M
Int J Cancer; 2013 Jun; 132(11):2597-605. PubMed ID: 23169448
[TBL] [Abstract][Full Text] [Related]
12. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
14. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
15. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer.
Asher V; Lee J; Innamaa A; Bali A
Clin Transl Oncol; 2011 Jul; 13(7):499-503. PubMed ID: 21775277
[TBL] [Abstract][Full Text] [Related]
16. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease.
Zheng H; Gao Y
Int J Gynecol Cancer; 2012 Jul; 22(6):1000-5. PubMed ID: 22426406
[TBL] [Abstract][Full Text] [Related]
17. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
19. Early pregnancy sex steroids and maternal risk of epithelial ovarian cancer.
Schock H; Surcel HM; Zeleniuch-Jacquotte A; Grankvist K; Lakso HÅ; Fortner RT; Kaaks R; Pukkala E; Lehtinen M; Toniolo P; Lundin E
Endocr Relat Cancer; 2014; 21(6):831-44. PubMed ID: 25270324
[TBL] [Abstract][Full Text] [Related]
20. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
